Fragment-based discovery of 6-substituted isoquinolin-1-amine based ROCK-I inhibitors

被引:28
作者
Ray, Peter [1 ]
Wright, Jane [1 ]
Adam, Julia [1 ]
Bennett, Johnathan [1 ]
Boucharens, Sylviane [1 ]
Black, Darcey [1 ]
Cook, Andrew [1 ]
Brown, Angus R. [1 ]
Epemolu, Ola [1 ]
Fletcher, Dan [1 ]
Haunso, Anders [1 ]
Huggett, Margaret [1 ]
Jones, Phil [1 ]
Laats, Steven [1 ]
Lyons, Amanda [1 ]
Mestres, Jordi [1 ]
de Man, Jos [1 ]
Morphy, Richard [1 ]
Rankovic, Zoran [1 ]
Sherborne, Brad [1 ]
Sherry, Lorcan [1 ]
van Straten, Nicole [1 ]
Westwood, Paul [1 ]
Zaman, Guido Z. R. [1 ]
机构
[1] MSD, Discovery Res, Newhouse ML1 5SH, Lanark, Scotland
关键词
Rho kinase; ROCK-I; ROCK inhibitors; Fragment-based drug discovery; FBDD; STD NMR; RHO-KINASE; DESIGN; MIGRATION; TARGET;
D O I
10.1016/j.bmcl.2010.11.060
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Fragment-based NMR screening of a small literature focused library led to identification of a historical thrombin/FactorXa building block, 17A, that was found to be a ROCK-I inhibitor. In the absence of an X-ray structure, fragment growth afforded 6-substituted isoquinolin-1-amine derivatives which were profiled in the primary ROCK-I IMAP assay. Compounds 23A and 23E were selected as fragment optimized hits for further profiling. Compound 23A has similar ROCK-1 affinity, potency and cell based efficacy to the first generation ROCK inhibitors, however, it has a superior PK profile in C57 mouse. Compound 23E demonstrates the feasibility of improving ROCK-1 affinity, potency and cell based efficacy for the series, however, it has a poor PK profile relative to 23A. (C) 2010 Published by Elsevier Ltd.
引用
收藏
页码:97 / 101
页数:5
相关论文
共 32 条
[1]   Regulation and functions of Rho-associated kinase [J].
Amano, M ;
Fukata, Y ;
Kaibuchi, K .
EXPERIMENTAL CELL RESEARCH, 2000, 261 (01) :44-51
[2]  
BOYCERUSTAY JM, 2010, J PAIN 0323
[3]   Protein kinase a in complex with rho-kinase inhibitors Y-27632, fasudil, and H-1152P: Structural basis of selectivity [J].
Breitenlechner, C ;
Gassel, M ;
Hidaka, H ;
Kinzel, V ;
Huber, R ;
Engh, RA ;
Bossemeyer, D .
STRUCTURE, 2003, 11 (12) :1595-1607
[4]   Targeting Rho and Rho-kinase in the treatment of cardiovascular disease [J].
Budzyn, K ;
Marley, PD ;
Sobey, CG .
TRENDS IN PHARMACOLOGICAL SCIENCES, 2006, 27 (02) :97-104
[5]   Rho-kinase inhibitor, Y-27632, has an antinociceptive effect in mice [J].
Buyukafsar, Kansu ;
Yalcin, Ipek ;
Kurt, A. Hakan ;
Tiftik, R. Nalan ;
Seyhan, Sahan-Firat ;
Aksu, Fazilet .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2006, 541 (1-2) :49-52
[6]   Recent developments in fragment-based drug discovery [J].
Congreve, Miles ;
Chessari, Gianni ;
Tisi, Dominic ;
Woodhead, Andrew J. .
JOURNAL OF MEDICINAL CHEMISTRY, 2008, 51 (13) :3661-3680
[7]   Rho-kinase inhibition: a novel therapeutic target for the treatment of cardiovascular diseases [J].
Dong, Ming ;
Yan, Bryan P. ;
Liao, James K. ;
Lam, Yat-Yin ;
Yip, Gabriel W. K. ;
Yu, Cheuk-Man .
DRUG DISCOVERY TODAY, 2010, 15 (15-16) :622-629
[8]   Development of dihydropyridone indazole amides as selective Rho-kinase inhibitors [J].
Goodman, Krista B. ;
Cui, Haifeng ;
Dowdell, Sarah E. ;
Gaitanopoulos, Dimitri E. ;
Ivy, Robert L. ;
Sehon, Clark A. ;
Stavenger, Robert A. ;
Wang, Gren Z. ;
Viet, Andrew Q. ;
Xu, Weiwei ;
Ye, Guosen ;
Semus, Simon F. ;
Evans, Christopher ;
Fries, Harvey E. ;
Jolivette, Larry J. ;
Kirkpatrick, Robert B. ;
Dul, Edward ;
Khandekar, Sanjay S. ;
Yi, Tracey ;
Jung, David K. ;
Wright, Lois L. ;
Smith, Gary K. ;
Behm, David J. ;
Bentley, Ross ;
Doe, Christopher P. ;
Hu, Erding ;
Lee, Dennis .
JOURNAL OF MEDICINAL CHEMISTRY, 2007, 50 (01) :6-9
[9]   Rho kinase as potential therapeutic target for cardiovascular diseases: opportunities and challenges [J].
Hu, E ;
Lee, D .
EXPERT OPINION ON THERAPEUTIC TARGETS, 2005, 9 (04) :715-736
[10]   The structure of dimeric ROCK I reveals the mechanism for ligand selectivity [J].
Jacobs, M ;
Hayakawa, K ;
Swenson, L ;
Bellon, S ;
Fleming, M ;
Taslimi, P ;
Doran, J .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2006, 281 (01) :260-268